Latest Intellectual Property News

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

BrainChip Holdings has initiated tape-out for its AKD1500 neuromorphic AI chip, targeting volume production by late Q3 2026 to meet rising demand for ultra-low-power edge AI solutions.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

FortifAI Limited reported steady revenue and significant cost reductions in Q1 FY26, while securing new contracts and advancing AI initiatives to boost operational efficiency.

PARKD Limited has successfully closed its Share Purchase Plan, raising $220,000; well above the initial $120,000 target; following a recent $780,000 placement. This capital boost underscores strong shareholder confidence in the company’s innovative building solutions.

TrivarX Limited has announced the acquisition of Stabl-Im, a novel stable isotope MRI technology for early brain tumor detection, backed by a $4.2 million capital raise including investment from biotech leader Dr Daniel Tillett.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

WhiteHawk Limited has announced the listing of nearly 93.5 million free-attaching options issued under its August 2025 placement, exercisable at $0.02 and expiring in 2028. These options, approved by shareholders, could raise close to $1.87 million if fully exercised.

Latrobe Magnesium Limited (ASX – LMG) has launched an $8 million equity raising to fund the ramp-up of its magnesium metal production and advance feasibility studies for a larger commercial plant. The company’s patented hydromet process converts brown coal ash into sustainable magnesium with significantly lower emissions than global peers.